AU2009346606B2 - Treatment of heart failure with normal ejection fraction - Google Patents

Treatment of heart failure with normal ejection fraction Download PDF

Info

Publication number
AU2009346606B2
AU2009346606B2 AU2009346606A AU2009346606A AU2009346606B2 AU 2009346606 B2 AU2009346606 B2 AU 2009346606B2 AU 2009346606 A AU2009346606 A AU 2009346606A AU 2009346606 A AU2009346606 A AU 2009346606A AU 2009346606 B2 AU2009346606 B2 AU 2009346606B2
Authority
AU
Australia
Prior art keywords
perhexiline
pharmaceutically acceptable
acceptable salt
used according
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009346606A
Other languages
English (en)
Other versions
AU2009346606A1 (en
Inventor
Houman Ashrafian
Michael Paul Frenneaux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heart Metabolics Ltd
Original Assignee
Heart Metabolics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heart Metabolics Ltd filed Critical Heart Metabolics Ltd
Publication of AU2009346606A1 publication Critical patent/AU2009346606A1/en
Application granted granted Critical
Publication of AU2009346606B2 publication Critical patent/AU2009346606B2/en
Assigned to HEART METABOLICS LIMITED reassignment HEART METABOLICS LIMITED Request for Assignment Assignors: HEART METABOLICS LIMITED
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2009346606A 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction Ceased AU2009346606B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2009/050539 WO2010133815A1 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Publications (2)

Publication Number Publication Date
AU2009346606A1 AU2009346606A1 (en) 2012-01-19
AU2009346606B2 true AU2009346606B2 (en) 2016-06-02

Family

ID=41213178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009346606A Ceased AU2009346606B2 (en) 2009-05-20 2009-05-20 Treatment of heart failure with normal ejection fraction

Country Status (11)

Country Link
US (3) US8440697B2 (enExample)
EP (1) EP2432470A1 (enExample)
JP (1) JP2012527438A (enExample)
CN (1) CN102573844A (enExample)
AU (1) AU2009346606B2 (enExample)
BR (1) BRPI0924398A2 (enExample)
CA (1) CA2816448A1 (enExample)
IL (1) IL216362A0 (enExample)
MX (1) MX2011012310A (enExample)
WO (1) WO2010133815A1 (enExample)
ZA (1) ZA201109332B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405381D0 (en) 2004-03-10 2004-04-21 Univ Wales Medicine A method and means for treating heart failure
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US10137093B2 (en) 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
WO2014036603A1 (en) * 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
MX2019007125A (es) 2016-12-15 2019-09-16 Baxter Int Sistema y metodo para monitorizar y determinar parametros de paciente a partir de forma de onda venosa detectada.
US11039754B2 (en) 2018-05-14 2021-06-22 Baxter International Inc. System and method for monitoring and determining patient parameters from sensed venous waveform

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087233A1 (en) * 2004-03-10 2005-09-22 Heart Metabolics Limited Perhexilin for treating chronic heart failure
WO2009066085A1 (en) * 2007-11-23 2009-05-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN380695A0 (en) 1995-06-23 1995-07-20 Queen Elizabeth Hospital, The Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
US20030162824A1 (en) 2001-11-12 2003-08-28 Krul Elaine S. Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor
CL2004000366A1 (es) 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
WO2005097121A1 (en) 2004-04-06 2005-10-20 Angiogenetics Sweden Ab Angiogenesis-affecting compounds and methods of use thereof
DE602006011363D1 (de) 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ITRM20060090A1 (it) 2006-02-22 2007-08-23 Sigma Tau Ind Farmaceuti Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
GB0908193D0 (en) 2009-05-13 2009-06-24 Albright Patents Treatment of disease state
US20140019207A1 (en) 2012-07-11 2014-01-16 Sap Ag Interactive in-memory based sales forecasting
WO2014036603A1 (en) 2012-09-05 2014-03-13 Adelaide Research & Innovation Pty Ltd Uses of (-)-perhexiline
WO2015131231A1 (en) 2014-03-03 2015-09-11 Adelaide Research & Innovation Pty Ltd Methods for using (-)-perhexiline

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087233A1 (en) * 2004-03-10 2005-09-22 Heart Metabolics Limited Perhexilin for treating chronic heart failure
WO2009066085A1 (en) * 2007-11-23 2009-05-28 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction

Also Published As

Publication number Publication date
ZA201109332B (en) 2012-08-29
US8440697B2 (en) 2013-05-14
US20130210719A1 (en) 2013-08-15
JP2012527438A (ja) 2012-11-08
EP2432470A1 (en) 2012-03-28
CA2816448A1 (en) 2010-11-25
IL216362A0 (en) 2012-01-31
US9468634B2 (en) 2016-10-18
US20130210720A1 (en) 2013-08-15
US20100331364A1 (en) 2010-12-30
MX2011012310A (es) 2012-04-11
WO2010133815A1 (en) 2010-11-25
CN102573844A (zh) 2012-07-11
AU2009346606A1 (en) 2012-01-19
US9457017B2 (en) 2016-10-04
BRPI0924398A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
US9457017B2 (en) Treatment of heart failure
AU2010247120B2 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (HCM)
Kahn et al. Radionuclide assessment of left ventricular diastolic filling in diabetes mellitus with and without cardiac autonomic neuropathy
AU2009252897B2 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
US8697677B2 (en) Perhexiline for treating chronic heart failure
EP1017376A1 (en) Method of treating heart failure
KR20250056200A (ko) 폐쇄성 비대심장근육병증 치료 방법
Gelzer et al. Management of atrial fibrillation
Lundström et al. Differential effects of xamoterol and verapamil on ventricular rate regulation in patients with chronic atrial fibrillation
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
Ishizu et al. Left ventricular longitudinal strain as a marker for point of no return in hypertensive heart failure treatment
JP2015147787A (ja) 正常駆出率心不全の治療
Iwashima et al. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan
US20250295639A1 (en) Methods for treating heart diseases
RU2195179C2 (ru) Способ диагностики жизнеспособного миокарда
WO2017021283A1 (en) Substance selected among midodrine, a pharmaceutical salt and an active metabolite thereof, for use in the treatment of obstructive cardiopathy
Energy Exercise Physiology
Abd El Azeem et al. Evaluation of aggressive heart rate reduction in patients with stable angina
Sindone et al. Chronic heart failure: Improving life with modern therapies
Begley Modifying Factors in the Phenotypic Expression of Hypertrophic Cardiomyopathy
Damy et al. ORIGINAL ARTICLE Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects.
Abozguia Metabolic alterations in patients with heart disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HEART METABOLICS LIMITED

Free format text: FORMER APPLICANT(S): HEART METABOLICS LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired